To date, considering the few data concerning the resistance mechanisms to immune check point inhibition in different tumor types, we can only speculate that PTEN loss should be considered a potential biomarker for the combined treatment with PD-1/PD-L1 targeting agents and PI3K inhibitors. The gene discussed is CD274; the disease is neoplasm.